Digital CBT‐I in Comorbid Insomnia and Depression: Clinical Outcomes From a Pragmatic Randomized Controlled Trial

Depression affects 8.1% of the German population annually, yet many patients remain resistant to conventional treatments. Given that 85% of individuals with depression also experience chronic insomnia, sleep may represent both a contributing and modifiable treatment factor. This study examines whether adding a fully automated digital cognitive behavioral therapy for insomnia (dCBT-I) to care-as-usual (CAU) improves depressive symptoms. Participants with comorbid depression and insomnia were randomized to either the intervention group (dCBT-I) or the waiting group (WLC). The intervention was delivered via a mobile app or web platform, consisting of 10 sequential core modules based on evidence-based CBT-I techniques. Assessments took place at baseline, 12- and 24-weeks post randomization. The primary outcome was the severity of depressive symptoms (Patient Health Questionnaire-9; PHQ-9). Secondary outcomes included insomnia severity, daytime sleepiness, fatigue, well-being and mechanistic effect measures. Linear mixed models were calculated to determine between-group effects. A total of 140 participants (120 women, mean age: <i>M</i> = 39.76 ± 11.65 years) were randomized to dCBT-I (<i>n</i>=70) or WLC (<i>n</i>=70). Large treatment effects at 12- and 24 weeks showed significant reductions in depressive symptoms (-3.34 and -2.83; <i>p</i>s <0.001; <i>d</i>s = 0.66-0.78) in the dCBT-I group. Treatment effects in favor of dCBT-I were also found for insomnia severity (<i>d</i>s = 1.46-1.94) and most secondary outcomes (<i>d</i>s = 0.33-1.14). This study demonstrates that digital dCBT-I can be effective not only for individuals with primary insomnia but also for those with depression. These findings align with previous research, highlighting the crucial role of sleep disturbances in depression management. Moreover, the effects remained stable even in the heterogeneous sample investigated in this study, reinforcing the robustness of dCBT-I across diverse patient groups. Thus, dCBT-I emerges as a promising adjunctive treatment. Considering these findings, it is essential to explore the integration of sleep-focused interventions into standard depression treatment. <b>Trial Registration:</b> German Clinical Trial Registry identifier: DRKS00030919.